Journal article
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
LA Emens, L Molinero, S Loi, HS Rugo, A Schneeweiss, V Diéras, H Iwata, CH Barrios, M Nechaeva, A Nguyen-Duc, SY Chui, A Husain, EP Winer, S Adams, P Schmid
Journal of the National Cancer Institute | Published : 2021
DOI: 10.1093/jnci/djab004
Abstract
Background: Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy from the phase 3 IMpassion130 trial, immune biomarkers and BRCA1/2 alterations were evaluated for association with clinical benefit with atezolizumab and nab-paclitaxel (A+nP) vs placebo and nP in unresectable (P+nP) locally advanced or metastatic triple-negative breast cancer. Methods: Patients were randomly assigned 1:1 to nab-paclitaxel 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) and atezolizumab 8..
View full abstractGrants
Funding Acknowledgements
This study was sponsored by F. HoffmannLa Roche Ltd/Genentech, Inc, a member of the Roche Group. We thank the patients participating in this trial and their families and the nurses, research coordinators, data managers, and clinical study site investigators. Medical writing assistance for this manuscript was provided by Steffen Biechele, PhD, and Ashley J. Pratt, PhD, of Health Interactions, Inc, and funded by F. Hoffmann-La Roche, Ltd.